Organon
120 articles about Organon
-
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
4/8/2024
Organon, a global healthcare company with a focus on women’s health, will release its first quarter 2024 financial results on May 2, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
-
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
4/8/2024
Shanghai Henlius Biotech, Inc. and Organon announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® biosimilar HLX14 met the primary endpoints.
-
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies
2/20/2024
Organon, a global healthcare company with a focus on women's health, embarks on the next phase of programming for "Her Plan is Her Power," to improve access and outcomes related to unplanned pregnancy in the U.S.
-
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
2/15/2024
Organon announced its results for the fourth quarter and full year ended December 31, 2023.
-
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
2/1/2024
Organon will release its fourth quarter and full year 2023 financial results on February 15, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
-
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
1/10/2024
Organon ’ s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older.
-
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/21/2023
Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2024, at 1:30 p.m. PT.
-
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
12/18/2023
Organon becomes the sole distributor and promoter of Emgality ® (galcanezumab) and RAYVOW ™ (lasmiditan) in Europe, building on strong commercial expertise in central nervous system disorders.
-
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
Organon announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.
-
Organon Reports Results for the Third Quarter Ended September 30, 2023
11/2/2023
Organon announced its results for the third quarter ended September 30, 2023.
-
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
11/1/2023
Organon and Sempre Health announced a strategic partnership designed to motivate eligible patients to refill their prescriptions on time and improve adherence through an innovative pricing program that offers personalized support.
-
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
10/19/2023
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2023 financial results on November 2, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
-
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
9/5/2023
Organon announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research, strengthening the company’s global clinical and medical capabilities, advancing external relationships and fueling efforts to bring forward innovations to solve unmet health needs.
-
Organon Reports Results for the Second Quarter Ended June 30, 2023
8/8/2023
Organon (NYSE: OGN) today announced its results for the second quarter ended June 30, 2023.
-
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
8/1/2023
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira ® (adalimumab).
-
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
7/17/2023
Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
-
REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
7/5/2023
Organon & Co. & Samsung Bioepis Co., Ltd. announced that HADLIMA™, a biosimilar referencing Humira, is now available to patients in the United States.
-
AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.
-
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
7/1/2023
Organon & Co. & Samsung Bioepis Co., Ltd. announced that HADLIMA™, a biosimilar referencing Humira, is now available to patients in the United States.
-
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
6/27/2023
Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report.